We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+11.2%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.54B
AUM Growth
+$718M
Cap. Flow
-$27.8M
Cap. Flow %
-0.29%
Top 10 Hldgs %
34.85%
Holding
152
New
15
Increased
35
Reduced
32
Closed
15

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$196M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$129M
3
GILD icon
Gilead Sciences
GILD
+$84.7M
4
VTRS icon
Viatris
VTRS
+$64.4M
5
BIIB icon
Biogen
BIIB
+$51.1M

Top Sells

Rank Stock Value
1
CNC icon
Centene
CNC
+$118M
2
PFE icon
Pfizer
PFE
+$98M
3
HCA icon
HCA Healthcare
HCA
+$97.1M
4
THC icon
Tenet Healthcare
THC
+$94.8M
5
AGN.PRA
Allergan plc
AGN.PRA
+$73.9M

Sector Composition

Rank Sector Weight
1 Healthcare 92.6%
2 Financials 1.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONC
51
BeOne Medicines Ltd
ONC
$34B
$57.9M 0.61%
1,287,588
+383,888
+42% +$15.1M
SEM
52
DELISTED
Select Medical
SEM
$56.6M 0.59%
6,843,814
+2,971,641
+77% +$22.3M
GWPH
53
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$56.2M 0.59%
561,071
+85,171
+18% +$9.17M
HCA icon
54
HCA Healthcare
HCA
$91.4B
$52.1M 0.55%
597,400
-1,147,600
-66% -$97.1M
ALNY icon
55
Alnylam Pharmaceuticals
ALNY
$38.2B
$51M 0.53%
639,200
+557,000
+678% +$35.6M
BMY icon
56
Bristol-Myers Squibb
BMY
$129B
$48.7M 0.51%
874,700
-1,036,300
-54% -$56.4M
ISRG icon
57
Intuitive Surgical
ISRG
$127B
$45.1M 0.47%
433,800
-19,800
-4% -$1.9M
SYK icon
58
Stryker
SYK
$134B
$43.9M 0.46%
316,300
– –
IMMU
59
DELISTED
Immunomedics Inc
IMMU
$43.5M 0.46%
4,928,958
+3,696,858
+300% +$26M
NTLA icon
60
Intellia Therapeutics
NTLA
$1.54B
$42.6M 0.45%
2,662,180
– –
BLUE
61
DELISTED
bluebird bio
BLUE
$42M 0.44%
30,865
+8,956
+41% +$10.8M
DERM
62
DELISTED
Dermira, Inc.
DERM
$41.3M 0.43%
1,418,873
+395,200
+39% +$12M
NBRV
63
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$41.1M 0.43%
15,678
+8,966
+134% +$23.1M
PVLA
64
Palvella Therapeutics
PVLA
$2.07B
$36.7M 0.39%
90,745
– –
RNAC icon
65
Cartesian Therapeutics
RNAC
$217M
$36.6M 0.38%
61,427
– –
EVHC
66
DELISTED
Envision Healthcare Holdings Inc
EVHC
$36.2M 0.38%
+578,100
New +$33.3M
MNTA
67
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$35.6M 0.37%
2,109,068
– –
EHTH icon
68
eHealth
EHTH
$42.2M
$34.5M 0.36%
1,834,700
+14,700
+0.8% +$235K
NVRO
69
DELISTED
NEVRO CORP.
NVRO
$33.6M 0.35%
451,300
+373,500
+480% +$29.9M
RDUS
70
DELISTED
Radius Health, Inc.
RDUS
$31.8M 0.33%
704,100
– –
OTIC
71
DELISTED
Otonomy, Inc.
OTIC
$29.4M 0.31%
1,559,074
-291,020
-16% -$4.06M
IMGN
72
DELISTED
Immunogen Inc
IMGN
$28M 0.29%
3,938,272
-2,157,375
-35% -$9.87M
JUNO
73
DELISTED
Juno Therapeutics, Inc.
JUNO
$27.4M 0.29%
+915,208
New +$22.6M
STDY
74
DELISTED
SteadyMed Ltd
STDY
$26.8M 0.28%
4,246,196
+1,174,000
+38% +$7.98M
IOVA icon
75
Iovance Biotherapeutics
IOVA
$2.09B
$25.2M 0.26%
3,382,900
– –
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q2 2017 Portfolio in Review

As of Q2 2017, OrbiMed held 152 positions worth $9.54B, up 8.1% from $8.82B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed's Q2 2017 filing shows 15 new, 35 increased, 32 reduced and 15 closed positions. Its largest new stake was Cigna: 1,222,100 shares worth $205M. The largest sale was Centene, an estimated $118M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q2 2017 buy was Cigna: 1,222,100 shares worth $205M.
  • OrbiMed added most to Gilead Sciences in Q2 2017, an estimated $84.7M increase.
  • OrbiMed's biggest Q2 2017 reduction was Pfizer, cutting an estimated $98M.
  • OrbiMed fully exited Centene in Q2 2017, selling an estimated $118M.
  • OrbiMed's ten largest holdings make up 35% of its $9.54B portfolio in Q2 2017.
  • OrbiMed opened 15 new positions and closed 15 in Q2 2017.
  • OrbiMed's portfolio value rose 8.1% quarter-over-quarter to $9.54B.

Based on OrbiMed's 13F filing for Q2 2017, filed 14 Aug 2017.